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Background: Comparisons of hormones such as dihydrotestosterone (DHT), estradiol (E2), and testosterone
indicate their impact on metabolism and body composition. While less is known regarding DHT and E2,
testosterone is an androgenic metabolic hormone capable of positively regulating a variety of anabolic and
androgenic processes in the body. Accordingly, it has been postulated that the age-related reduction in serum
testosterone levels leads to reductions in lean muscle mass, bone mineral density, and other physical conditions
that impair physical performance and decrease quality of life. Preliminary studies suggest that key ingredients found
in Resettin®/MyTosterone™, a natural supplement containing the carotenoid astaxanthin from Haematococcus
pluvialis and Saw Palmetto berry lipid extract from Serenoa repens, could positively impact testosterone levels.
To investigate the clinical efficacy of Resettin®, the serum profiles of testosterone, E2 and DHT in healthy sedentary
males before and after Resettin® treatment were evaluated in a randomized, placebo controlled clinical trial.
Method: Twenty healthy, sedentary men between the ages of 21 and 70 were randomized into either an 800 mg/day
or 1200 mg/day Resettin®/MyTosterone™ treatment group or lecithin, which was used as the placebo. After a 14-day
treatment period, there was a 14-day washout period. After the wash-out period, participants were crossed over within
their respective group to either Resettin®/MyTosterone™ or the lecithin placebo for 14 days.
Results: After 14 days, participants receiving 800 mg per day of Resettin® had significantly reduced baseline-subtracted
serum DHT levels in comparison to the placebo control group. While after 14 days, participants receiving 1200 mg per
day of Resettin® had significantly reduced baseline-subtracted serum DHT and E2 levels in comparison to the placebo
control group. Moreover, participants receiving 1200 mg per day of Resettin® experienced a 38% increase in serum
testosterone levels in comparison to the placebo control group, but the effect did not reach statistical significance.
Conclusion: Although additional studies will be required to evaluate how Resettin® may promote proper testosterone
regulation, these findings indicate that Resettin® can favorably influence serum hormone profiles in men.
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SarcopeniaBackground
Aging is associated with a decline in a variety of endocrine
functions including menopause in women and a deterior-
ation in androgen production in men [1]. Gradual reduc-
tions in testosterone levels can lead to many symptoms of
andropause including a lack of energy, decreased mental
acuity, a loss of overall well-being, and sexual dysfunction
[2-4]. Androgen deficiency in aging men may also occur
concomitantly with a geriatric syndrome called sarcopenia
or the loss of significant amounts of lean skeletal muscleCorrespondence: mark.anderson@consumerlab.com
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unless otherwise stated.mass [5]. Sarcopenia is significantly associated with a
variety of adverse outcomes which can result in increased
incidences of slips, trips and falls leading to bone fractures,
hospitalization and physical disability leading to a poor
quality of life [6].
Although the causal factors leading to sarcopenia are
complex and multifactorial, there is a clear association
between age-related decreases in testosterone levels and
increased incidences of sarcopenia [2,6]. In males, tes-
tosterone is predominantly synthesized by Leydig cells
of the testes using the steroid biosynthesis pathway.
Testosterone acts on target cells expressing the androgen. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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the anabolic growth of muscle and an increase bone dens-
ity, as well as the androgenic maturation of sex organs.
Testosterone levels are directly regulated by 5α-reductase,
an enzyme which catalyzes and regulates the synthesis of
the more potent androgenic steroid hormone dihydrotes-
tosterone (DHT) from free testosterone, and aromatase,
an enzyme that directly converts testosterone into the
estrogenic steroid hormone estradiol [7].
As men age, bioavailable levels of testosterone decrease
by 2% per year after age 30 [8]. Given the role of testoster-
one in directly increasing the synthesis of muscle protein
and counteracting the catabolic effects of the hormone cor-
tisol in breaking down muscle, researchers and clinicians
have developed a variety of pharmacological treatment
modalities that aim to increase serum testosterone levels.
These approaches include the exogenous administration
of testosterone transdermally, through subcutaneous or
intramuscular injections, or by boosting endogenous tes-
tosterone through the pharmacological inhibition of 5α-
reductase inhibitors [9]. The latter approach is not a
common clinical strategy as inhibitory drugs only elicit
a moderate impact on testosterone (approximately 15%) in
conjunction with an increase in E2, gynecomastia, erectile
dysfunction, cataract formation, depressive symptoms, and
other mood disorders [4,10-14].
Currently, the most common approach for elevating
testosterone levels is through the use of selective estro-
gen receptor modulators (SERMs), human chorionic go-
nadotropin (HCG), or a combination of both. SERMs
block the effects of estrogen in the central nervous sys-
tem and breast in men, thereby reducing the occurrence
of gynecomastia and they also block the suppressive ef-
fect of estrogens on luteinizing hormone production,
which propagates testosterone production [15]. HCG is
structurally similar to the luteinizing hormone and it is
recognized by the body as luteinizing hormone, which in
turns signals the testes to begin producing more tes-
tosterone. However, SERMs also function as estrogen
agonists in the liver and this leads to an increase in
the production of the sex hormone binding globulin
(SHBG), which circulates in the blood and may irrevers-
ibly bind to testosterone and other sex hormones, causing
them to become inactive. As a result, SERMs therapy may
increase the total concentration of testosterone, but the
concentration of bioactive testosterone may remain low
[15]. Furthermore, testosterone therapy has the poten-
tial to disrupt the feedback cycle from the hypothal-
amus/pituitary to the testes [16].
With regard to CVD it is uncertain that any risk or
beneficial effects of increasing testosterone levels through
exogenous testosterone therapy, SERMS or HCG may
be different than the use of other approaches such as
the use of natural supplements and is continuouslyunder investigation. One such natural compound is Astax-
anthin (AX), a carotenoid with favorable pharmacokinetics
and bioavailability produced by Haematococcus algae
(pluvialis) [17]. AX is shown to inhibit both 5α-reductase
and aromatase CYP-19, which is an enzyme that converts
C19 androgens to aromatic C18 estrogenic steroids [18,19].
Moreover, findings from an open label dose response study
of a product containing AX provided some suggestion that
the compound may be involved in the regulation DHT and
E2 levels, even within three days of treatment [19]. Thus,
the primary aim of this study was to extend these findings
to men under the age of 50. To this end, the hormonal
response patterns of sedentary men was tested following
an administration of novel Resettin®/MyTosterone™, which
is a raw material consisting of AX and a lipid extract from
the saw palmetto berry.
Methods
Study design
A prospective single blind treatment vs. placebo study was
conducted over a 14 day period at Hunter Laboratories in
Walnut Creek, CA. Experimental groups of 20 healthy,
sedentary men between the ages of 21 and 70 years of age
with a body mass index of less than 27 kg/m2 were phlebo-
tomized following an overnight fast. Assignment to an ex-
perimental group was conducted in an alternating fashion,
based upon arrival time. The study consisted of two experi-
mental groups. In the low dose group, participants received
a dose of 800 mg/day. The high dose group received a dose
of 1200 mg/day. Study participants were asked to self-
administer two to three (depending on their experimental
group) soft-gelatin capsules daily containing either 400 mg
of Resettin® (Resettin®/MyTosterone™; Triarco Industries,
Wayne, NJ) or lecithin, which was used as the placebo.
Participants were randomized into either the 800 mg/day
or 1200 mg/day Resettin®/MyTosterone™ treatment group.
After a 14-day treatment period, participants discontinued
placebo or Resettin®/MyTosterone™ treatment for a con-
secutive 14 days. Following this 14-day washout period,
participants were crossed over within their respective
group to either Resettin®/MyTosterone™ or the lecithin pla-
cebo for 14 days. Blood was collected on days 0, 3, 7 and
14 days following the initiation of treatment. Serum hor-
mone levels were collected and analyzed. Patterns of
hormonal response were compared across the treatment
groups in a pairwise manner. Researchers attempted to
collect blood samples from all of the participants at appro-
ximately the same time of day in order to minimize circa-
dian variations in serum hormone levels.
Participants
A total of forty sedentary, healthy men between the ages
of 21 and 68 met inclusion criteria and were enrolled for
this study. Enrollment was voluntary, and participants
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the Human Subjects Guidelines of Western Institutional
Review Board and the American College of Sports Medi-
cine. Participants were excluded from study if they had a
history of smoking, pulmonary disease, hypertension, hepa-
torenal disease, musculoskeletal disorders, neuromuscular
or neurological diseases, autoimmune diseases, cancer, pep-
tic ulcers, or anemia. Participants were also excluded if they
exhibited repeated signs of benign prostate hypertrophy,
regularly consumed commercially available products con-
taining saw palmetto or AX, were taking ergogenic levels of
nutritional supplements that may affect muscle mass, such
as creatine, or exhibited anabolic hormone levels, such as
androstenedione or dehydroepiandrosterone. Participants
taking prescription medication for a heart condition, pul-
monary or thyroid problem were also excluded from the
study. Participants on anti-hyperlipidemia, hypoglycemic,
anti-hypertensive, endocrinologic, psychotropic, neuro-
muscular/neurological, or androgenic medications were
also not invited to enroll in the study. After a 10-hour
fast of all food or drink with caloric value along with a
48-hour rest from strenuous exercise, participants were
phlebotomized. Participant age, height, weight, body
mass index, resting heart rate, and blood pressure were
also collected at this time.Serum hormone quantification
Serum levels of testosterone, DHT, and E2 were deter-
mined by enzyme-linked immunosorbent assay (ELISA)
using commercially available kits (Alpha Diagnostic, San
Antonio, USA). Briefly, reference controls, standards and
samples were aliquoted in triplicate into separate wells
pre-incubated with horseradish peroxidase (HRP)-conju-
gated primary antibodies specific for either testosterone,
DHT, or E2. After washing, reference controls, standards,
and sample wells were incubated with tetramethylbenzi-
dine and gently agitated. After 10 min, the HRP-substrate
colorimetric reaction was stopped with 0.16 M H2SO4,
and the absorbance at 450 nm of each well was evaluated
using a spectrophotometer.Statistical analysis
To evaluate the significance of possible group dif-
ferences in steroid hormone levels within treatment
groups, a 2 (high versus low dose) × 4 (sample time
point) one-way repeated measures Analysis of Variance
(ANOVA) was conducted. To evaluate statistically sig-
nificant differences in steroid hormone levels between
treatment groups, a two-way ANOVA was used. Differ-
ences in steroid hormone concentrations were consid-
ered clinically significant when the probability of a Type
I error was less than 0.05.Results and discussion
Total testosterone levels tend to decline as men age [7].
Given that natural 5α-reductase/aromatase inhibitors,
such as AX, may increase serum testosterone [9,18,19],
we set out to determine if Resettin® was capable of in-
creasing serum testosterone levels in sedentary men. To
that end, a randomized controlled clinical dose compari-
son study of Resettin® was completed.
Body weight, blood pressure, and tolerance
The average baseline body weight of participants within the
800 mg/day placebo and Resettin®/MyTosterone™ treatment
groups were 88.3 kg and 93 kg, respectively. The average
baseline body weight of participants within 1200 mg/day
placebo and Resettin®/MyTosterone™ treatment groups
were 103.7 kg and 95.8 kg, respectively. Results indicated
that there were no clinically significant changes in average
body weight over the duration of the study.
The average baseline systolic diastolic blood pressure
ratios were 120 mmHg over 82 mmHg in the 800 mg/day
placebo control group, 125 mmHg over 83 mmHg in the
800 mg/day Resettin®/MyTosterone™ treatment group,
122 mmHg over 82 mmHg in the 1200 mg/day placebo
control group and 122 mmHg over 81 mmHg in the
1200 mg/day Resettin®/MyTosterone™ treatment group.
No significant changes in systolic or diastolic blood pres-
sure were observed over the course of the study. Owing to
the significant safety profile and tolerability of AX as well
as the other constituent compounds of Resettin®, there
were no reports of adverse side effects during the study.
Serum testosterone, E2, and DHT levels after Resettin®/
MyTosterone™ treatment
To test for changes in serum testosterone level in re-
sponse to Resettin®/MyTosterone™, participants were
asked to self-administer orally either 800 mg/day or
1200 mg/day of Resettin®/MyTosterone™. In terms of the
1200 mg/day experimental group, the average serum tes-
tosterone levels were higher following 14 days as com-
pared to the levels measured at baseline (day 0). For the
800 mg/day Resettin®/MyTosterone™ treatment group,
the level of serum testosterone did not differ signifi-
cantly between baseline and following 14 consecutive
days of treatment (ANOVA-RM; p > 0.05). Serum testos-
terone levels for both groups are illustrated graphically
in Figure 1. Furthermore, the results indicated that the
serum testosterone levels of participants who were ad-
ministered 1200 mg/day of Resettin®/MyTosterone™
were 38.04% higher than the serum testosterone levels
of participants in the placebo control group Figure 1.
However, there were no statistically significant differ-
ences in the average serum testosterone levels of either
the 800 mg/day or 1200 mg/day Resettin®/MyToster-
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Figure 1 Baseline subtracted serum testosterone levels in placebo- and Resettin®/MyTosterone™-treated participants. Shown are the
total serum testosterone levels from participants after 3, 7 and 14 days of 800 mg/day placebo (a) or Resettin®/MyTosterone™, or 1200 mg/day
placebo or Resettin®/MyTosterone™ (b) as determined by ELISA. Each experimental group had between 9 and 10 participants, and results are
indicative of one trial. Error bars denote standard deviation of the experimental mean.
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RM; p > 0.05).
Given that aromatase is capable of converting testoster-
one into E2, the serum concentrations of E2 were also
evaluated by ELISA in all participants. Serum E2 levels did
not significantly change relative to baseline levels. Further,
there were no significant differences in the average serum
E2 levels of the participants in the 800 mg/day and
1200 mg/day Resettin®/MyTosterone™ treatment groups
as compared to the placebo control groups (Figure 2;
ANOVA-RM; p > 0.05). Interestingly, when all serum E2
concentrations were adjusted by subtracting their baseline
concentrations, results revealed a statistically significant
reduction in the average serum E2 concentration of the
1200 mg/day Resettin®/MyTosterone™ treatment group
compared to that of the 1200 mg/day placebo control
group (Figure 2; ANOVA-2; p < 0.05).Figure 2 Baseline subtracted serum E2 levels in placebo- and Resettin
levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Re
MyTosterone™ (b) as determined by ELISA. Each experimental group had b
There was a statistically significant reduction in the average serum E2 conc
group compared to that of the 1200 mg/day placebo control group (ANOV
experimental mean. An asterisk (*) indicates statistical significance.The increase in serum testosterone levels for the
1200 mg per day of Resettin®/MyTosterone™ treatment
group after 14 days was not statistically significant in
comparison to the placebo group. However, there was a
statistically significant decrease in the DHT levels in the
800 mg/day and 1200 mg/day Resettin®/MyTosterone™
treatment groups compared to their respective placebo
control groups (Figure 3; ANOVA-RM; p < 0.05). Con-
sistent with this data were the baseline-subtracted serum
DHT levels in the 1200 mg/day Resettin®/MyTosterone™
treatment group which significantly decreased when
compared to the serum DHT levels of the 1200 mg/day
placebo control group (Figure 3; ANOVA-2; p < 0.05).
These findings suggest that Resettin®/MyTosterone™ at
the tested concentrations (800 mg/day and 1200 mg/day)
do not significantly impact the serum levels of testos-
terone in sedentary men, but may have an impact on®/MyTosterone™-treated participants. Shown are the serum E2
settin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/
etween 9 and 10 participants, and results are indicative of one trial.
entration of the 1200 mg/day Resettin®/MyTosterone™ treatment
A-2; p < 0.05). Error bars denote standard deviation of the
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prevent the further reduction of testosterone levels.
Conclusions
Deficiencies in testosterone production and the deregula-
tion of testosterone’s anabolic activities are hallmarks of
an aging endocrine system [1]. It is well-established that
decreases in testosterone level are associated with a variety
of medical problems, including a decline in cognitive func-
tion, loss of libido, loss of lean muscle mass and strength,
and reductions in bone mineral density [2-4]. While the
administration of exogenous testosterone can greatly
ameliorate the deleterious effects of a testosterone defi-
ciency, adverse side effects such as an imbalance in the
hypothalamic-pituitary axis associated with this type of
treatment option [16,20]. By naturally increasing endogen-
ous testosterone levels, the goal is to target the human
body’s own well-regulated hypothalamic-pituitary-gonadal
axis, whose function is to maintain homeostasis.
Published research suggests that supplementing AX
may have inhibitory effects on 5α-reductase, thus, the
primary aim of the current study was to evaluate the
effects of the natural supplement, called Resettin®, on
serum testosterone levels [18,19]. Specifically, it was hy-
pothesized that individuals who undergo treatment with
Resettin® would have significantly higher serum levels of
testosterone than those receiving the placebo. As illus-
trated in Figure 1, there were no statistically significant
changes in serum testosterone levels following 14 days
of treatment.
These findings are somewhat surprising, as they are in
contrast to similar existing studies within the literature
that demonstrated an elevation of testosterone after
therapeutic treatment [9,15]. Specifically, a number of
previous studies have indeed found significant increases
in serum testosterone levels within populations of men.Figure 3 Baseline subtracted serum DHT levels in placebo- and Reset
levels from participants after 3, 7 and 14 days of 800 mg/day placebo or Re
MyTosterone™ (b) as determined by ELISA. Each experimental group had b
There was a statistically significant decrease in the DHT levels in the 800 m
compared to their respective placebo control groups (ANOVA-RM; p < 0.05
An asterisk (*) indicates statistical significance.Differences in terms of the participant population may
account for why the present findings failed to support
that of the extant literature. Specifically, there were
meaningful differences in terms of the mean participant
age across studies (i.e., 55.6 versus 41.2 years of age).
Thus, age-related changes likely explain the lack of sig-
nificant findings, as it is expected that the way that the
body metabolizes, or processes, various supplements will
produce variable results within and between populations.
Changes related to typical aging are also likely have sig-
nificant impacts on all processes within the body, and
the synthesis of testosterone is no different. Moreover,
other differences in sample population characteristics
likely account for the divergent findings across these
studies.
More specifically, compared to a non-placebo con-
trolled trial conducted by Angwafor and Anderson [19],
the present sample had many unique characteristics,
which may be meaningful in terms of the generalizability
of these data. For example, mean baseline concentra-
tions of serum testosterone across the groups were mea-
sured to be less than half of the observed concentration
levels at baseline in the previous study. Initial observa-
tion of DHT concentration across the groups were al-
most three times higher in the present study than the
baseline DHT serum concentrations observed across all
groups in the previous study. Baseline concentrations of
estradiol between the two studies were even more diver-
gent. Serum concentrations of estradiol at baseline
across the groups were nearly four times higher in the
current sample than that of the baseline serum estradiol
concentrations observed previously. This is suggestive of
underlying sample population characteristics that may
account for variable results and additional studies ex-
ploring for latent clinical profiles of the androgen re-
sponse to supplements are needed.tin®/MyTosterone™-treated participants. Shown are the serum DHT
settin®/MyTosterone™ (a), or 1200 mg/day placebo or Resettin®/
etween 9 and 10 participants, and results are indicative of one trial.
g/day and 1200 mg/day Resettin®/MyTosterone™ treatment group
). Error bars denote standard deviation of the experimental mean.
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to 15 kg more than the participants in the 2008 non-
placebo controlled trial [19]. A wealth of evidence exists
linking the accumulation of adipose tissue with detrimen-
tal metabolic changes within the body [21-24]. For in-
stance, the aromatase enzyme, which is found within
adipose tissue, is primarily responsible for converting
androgens into estrogen. Increases in adipose tissue have
been linked with higher serum concentrations of estrogens
and lower levels of serum testosterone [21,23]. As previ-
ously discussed, the men within the present sample exhib-
ited much higher serum estrogen concentrations than the
men in the previous study. Taken together, it is likely that
metabolic changes as a result of being overweight or obese
transform the manner in which the endocrine system is
influenced through exogenous factors, such as dietary
supplements.
In comparing serum estrogen concentration, responses
to Resettin®/MyTosterone™ were different across both
studies. Following baseline subtraction, average serum es-
trogen concentrations for an individual in the aforemen-
tioned study [19] were found to decrease significantly
from baseline to day 7 in the low dosage group (800 mg/
day), as well as from baseline to days 3, 7, and 14 in the
high dosage group (2000 mg/day). Interestingly, the
present study found similar patterns with a much lower
dose of the supplement such that serum estrogen concen-
trations were found to be lower on average for the high
dosage treatment group (1200 mg/day). The placebo
group, in contrast, exhibited higher concentrations of
estrogen overall. These data also support the idea that the
metabolic profiles of participants in the current sample
may not be comparable to that of the previous study,
owing to confounding factors related to higher amounts
of adipose tissue. Indeed, according to recently published
data, estrogen levels for adult males typically range from
between 37 to 110 pM [25]. Baseline concentration levels
of participants in the current study ranged from 85 to 90
pM, while they ranged from 21.5 to 24 pM in the previous
study. In conjunction, serum DHT concentrations were
much higher at baseline in the present sample compared
to the previous study. Interestingly, despite these differ-
ences, at day 14 the groups in both studies exhibited lower
concentrations of serum DHT when compared to the pla-
cebo group. More specifically, in the current study the low
dose group (800 mg/day) started out with concentrations
of 6 nM of serum DHT and dropped more than 0.6 nM
over the course of 14 days. Further, the high dosage group
(1200 mg/day) exhibited an increase in serum DHT con-
centrations to approximately 1 nM at day 14, while the
DHT levels for the placebo group also rose to approxi-
mately 2 nM. These data indicate that, given the likely
contribution of higher levels of adipose tissue among par-
ticipants in the present sample, it may be beneficial toexamine the endocrine response, particularly testosterone
levels, using a higher dose of Resettin®/MyTosterone™.
Further, individuals included in the present sample were
drawn from the U.S. population, while participants from
the previous study were drawn from a country in west
Central Africa. Thus, it is expected that factors related to
the diet of individuals within the present sample, charac-
terized as high in fats, sugars, and carbohydrates, as well
as physical conditions, play a significant role in accounting
for why the current data failed to replicate previous find-
ings. Additional studies are warranted to provide support
for the generalizability of these findings.
Further, the sample sizes across studies are relatively
small [19]. Thus, there is a high risk for confounding
factors that may have skewed the data. For instance, an
unmeasured characteristic of the men included within
the present study like higher levels of the aromatase
enzyme, may account for their lack of response to Reset-
tin®. Additional studies are warranted to more clearly de-
lineate the association between Resettin® and serum
testosterone levels. Findings from these studies are ex-
pected to improve the generalization of the conclusions.
Notwithstanding, there was a measurable 38% increase
in serum testosterone levels and a 4.5% decrease in
estradiol among participants receiving the 1200 mg/day
experimental group. Indeed, while this increase may not
have reached the stringent criteria for statistical signi-
ficance, this difference may be clinically relevant. Add-
itional studies are warranted to explore specific benefits
to this degree of improvement in testosterone level.
Moreover, given that serum DHT levels were signifi-
cantly lower in both the 800 mg/day and 1200 mg/day
treatment groups, and that Resettin®/MyTosterone™ has
been shown to prevent the conversion of testosterone
into DHT over time, it may be that this accounts for the
rising testosterone levels in a subset of participants.
Thus, additional studies that include a broader sample
of study participants are warranted to explore for the
generalizability of these findings. Future studies may also
be needed to examine dosage level in relation to weight
or BMI and androgen response. While weight specific
dosing is not novel in terms of the pharmaceutical field,
dietary supplements have not typically provided dosing
instructions that are dependent upon the individual’s
weight or BMI. It is expected that findings from studies
examining the impact of various dosages of Resettin®/
MyTosterone™ on the metabolic profiles, specifically tes-
tosterone, DHT, and estrogen levels, across individuals
who are overweight or obese will provide support for in-
cluding weight dependent dosing instructions and, thus,
improve the individual’s hormonal response to this nat-
ural dietary supplement.
Additional studies are necessary to evaluate the full
extent of the regulatory effects of Resettin® in the body’s
Anderson Journal of the International Society of Sports Nutrition 2014, 11:43 Page 7 of 7
http://www.jissn.com/content/11/1/43efforts to resume homeostasis and return testosterone to
ideal levels. This study highlights that there are likely ideal
levels of testosterone in men. These data contribute to the
possible benefits of using Resettin/Mytosterone for com-
bating age-related androgen deficiency and andropause.
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